{"id":60648,"title":"Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study.","abstract":"","date":"2014-07-04","categories":"Hemic and Lymphatic Diseases","split":"test","url":"http://www.ncbi.nlm.nih.gov/pubmed/24855212","annotations":[{"name":"Clinical trial","weight":0.835773,"wikipedia_article":"http://en.wikipedia.org/wiki/Clinical_trial"},{"name":"Dexamethasone","weight":0.780751,"wikipedia_article":"http://en.wikipedia.org/wiki/Dexamethasone"},{"name":"Multiple myeloma","weight":0.439644,"wikipedia_article":"http://en.wikipedia.org/wiki/Multiple_myeloma"},{"name":"Cyclophosphamide","weight":0.223912,"wikipedia_article":"http://en.wikipedia.org/wiki/Cyclophosphamide"},{"name":"Carfilzomib","weight":0.0297972,"wikipedia_article":"http://en.wikipedia.org/wiki/Carfilzomib"},{"name":"Drug metabolism","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/Drug_metabolism"},{"name":"Multicenter trial","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/Multicenter_trial"},{"name":"Phase (matter)","weight":0.0147415,"wikipedia_article":"http://en.wikipedia.org/wiki/Phase_(matter)"}]}
